Karuna Therapeutics Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Karuna Therapeutics stock.
View analyst ratings for Karuna Therapeutics or view top-rated stocks.

Wall Street analysts have given Karuna Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Karuna Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Karuna Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Karuna Therapeutics.

Karuna Therapeutics, Inc. (NASDAQ:KRTX) announced its quarterly earnings results on Thursday, February, 25th. The company reported ($0.89) EPS for the quarter, meeting analysts' consensus estimates of ($0.89).
View Karuna Therapeutics' earnings history.

Karuna Therapeutics' stock was trading at $78.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KRTX shares have increased by 42.9% and is now trading at $112.60.
View which stocks have been most impacted by COVID-19.

11 equities research analysts have issued 12 month target prices for Karuna Therapeutics' stock. Their forecasts range from $126.00 to $167.00. On average, they anticipate Karuna Therapeutics' stock price to reach $144.70 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price.
View analysts' price targets for Karuna Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Karuna Therapeutics include Teva Pharmaceutical Industries (TEVA), Dr. Reddy's Laboratories (RDY), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Maravai LifeSciences (MRVI), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Evotec (EVTCY), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX) and Ionis Pharmaceuticals (IONS).
View all of KRTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and The Walt Disney (DIS).

(KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Karuna Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Karuna Therapeutics stock include Andrew Craig Miller, Arch Venture Partners Ix, Llc, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends for Karuna Therapeutics.

KRTX stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Karuna Therapeutics company stock in the last year include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Puretech Health Llc, Stephen K Brannan, Steven M Paul, and Troy A Ignelzi.
View insider buying and selling activity for Karuna Therapeutics or view top insider-selling stocks.

Shares of KRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KRTX stock can currently be purchased for approximately $112.60.

Karuna Therapeutics has a market capitalization of $3.04 billion. The company earns $-43,960,000.00 in net income (profit) each year or ($3.68) on an earnings per share basis.

Karuna Therapeutics employs 63 workers across the globe.

The official website for Karuna Therapeutics is karunatx.com.

Karuna Therapeutics is headquartered at 33 ARCH STREET SUITE 3110, BOSTON MA, 02110.

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The company can be reached via phone at 857-449-2244 or via email at [email protected]